Doulamis Ilias P, Samanidis George, Tzani Aspasia, Antoranz Asier, Gkogkos Anastasios, Konstantopoulos Panagiotis, Pliaka Vaia, Minia Angeliki, Alexopoulos Leonidas G, Perrea Despina N, Perreas Konstantinos
Laboratory for Experimental Surgery and Surgical Research "N.S Christeas", Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.
First Department of Adult Cardiac Surgery, Onassis Cardiac Surgery Center, Athens, Greece.
Interact Cardiovasc Thorac Surg. 2019 Jan 1;28(1):94-101. doi: 10.1093/icvts/ivy210.
Proteomic analysis of patients with advanced cardiovascular disease was conducted to identify possible biomarkers for atrial fibrillation (AF).
A total of 123 patients undergoing cardiac surgery (22 with AF and 101 without AF) and 20 healthy subjects were recruited. Demographic data, patient history and blood samples were collected. Growth/differentiation factor 15, resistin, intracellular adhesion molecule-1, galectin-3, trefoil factor 3, tissue inhibitor of metalloproteinases 1, matrix metallopeptidase 9, high-sensitive troponin T, interleukins 6, 1α, 3, 4, 8, 20 and 22, tumour necrosis factor alpha, C-X-C motif chemokines 10 and 11, S100A6 and Type III procollagen were measured in blood serum. Differential expression between any 2 groups for any of the measured proteins was identified by fitting linear models, whereas Matthews Correlation Coefficient was used to evaluate their predictive capacity. Combined markers using more than 1 protein were attained via weighted Support Vector Machines.
Although serum levels of the markers were higher in patients with cardiovascular disease than in healthy subjects, only growth/differentiation factor 15 and resistin were significantly higher in patients with AF among the subpopulation who underwent heart surgery (P = 0.029 and P = 0.007, respectively). Specific pairs of several biomarkers had mediocre predictive capacity for AF.
Growth/differentiation factor 15 and resistin are 2 markers that could be helpful in stratifying risk for AF in patients with cardiovascular disease. Yet, more research in terms of proteomics and investigation of possible molecular pathways implicated is required.
对晚期心血管疾病患者进行蛋白质组学分析，以确定心房颤动（AF）的潜在生物标志物。
共招募了123例接受心脏手术的患者（22例患有AF，101例未患AF）和20名健康受试者。收集了人口统计学数据、患者病史和血液样本。检测了血清中的生长/分化因子15、抵抗素、细胞间黏附分子-1、半乳糖凝集素-3、三叶因子3、基质金属蛋白酶组织抑制因子1、基质金属蛋白酶9、高敏肌钙蛋白T、白细胞介素6、1α、3、4、8、20和22、肿瘤坏死因子α、C-X-C基序趋化因子10和11、S100A6和III型前胶原。通过拟合线性模型确定所测蛋白质在任意两组之间的差异表达，而马修斯相关系数用于评估其预测能力。使用加权支持向量机获得使用多种蛋白质的联合标志物。
尽管心血管疾病患者血清中这些标志物的水平高于健康受试者，但在接受心脏手术的亚组中，只有生长/分化因子15和抵抗素在AF患者中显著更高（分别为P = 0.029和P = 0.007）。几种生物标志物的特定组合对AF的预测能力一般。
生长/分化因子15和抵抗素是两种有助于对心血管疾病患者AF风险进行分层的标志物。然而，在蛋白质组学方面以及对可能涉及的分子途径的研究仍需更多探索。
